This site is intended for healthcare professionals

Novartis announces NEJM publication of three pivotal trials showing efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy.

Read time: 3 mins
Published:19th Mar 2020
Condition: Dyslipidaemia
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest